Invention Grant
- Patent Title: Tricyclic compounds as inhibitors of mutant IDH enzymes
-
Application No.: US15532552Application Date: 2015-12-01
-
Publication No.: US10508108B2Publication Date: 2019-12-17
- Inventor: Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , J. Michael Ellis , Sara Esposite , Dawn M. Hoffman , Chunhui Huang , Solomon D. Kattar , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Dann L. Parker, Jr. , Michael H. Reutershan , Nunzio Sciammetta , Pengcheng P. Shao , David L. Sloman , Wanying Sun , Feroze Ujjainwalla , Zhicai Wu , Yang Yu , Craig R. Gibeau
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Yong Zhao; Anna L. Cocuzzo
- International Application: PCT/US2015/063127 WO 20151201
- International Announcement: WO2016/089830 WO 20160609
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D471/14 ; C07D519/00
Abstract:
The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
Public/Granted literature
- US20170362220A1 NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES Public/Granted day:2017-12-21
Information query
